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ABSTRACT
EMOTION DYSREGULATION: A PREDICTOR FOR CBT TREATMENT OUTCOMES IN
A COMORBID PTSD AND SUD POPULATION
By
Jennifer Robin Wallach, M.P.H.
Adviser: Denise Hien, Ph.D.
Trauma has been shown to disrupt self-regulatory processes; emotion regulation deficits have
also been implicated in the initiation and maintenance of substance use disorders (SUDs).
Treatments for these complex comorbid problems utilize a variety of approaches. However, to
date, few studies have examined the effect of various available treatments on emotion
dysregulation in this population. This study extends the research on emotion regulation among
the population with comorbid posttraumatic stress disorder (PTSD) and SUD. This study is a
secondary analysis of part of the data from a randomized clinical trial assessing the relative
efficacy of two active treatment conditions for substance dependent individuals who also meet
criteria for current DSM-IV-TR PTSD. The current study examined features associated with
emotion dysregulation, correlating dysregulation with PTSD and SUD symptoms; the study
focused on baseline emotion dysregulation as a predictor of treatment outcomes. Additionally,
the study examined emotion dysregulation over time to determine the mutability of this complex
factor in response to treatment. Lastly, this study utilized a case illustration to examine in more
depth change in emotion dysregulation over time, as measured by physiological arousal; this
methodology provides for a more thorough depiction of the phenomenon. Correlation analyses
identified that baseline emotion dysregulation was associated with baseline PTSD symptom
severity, but not with baseline substance use frequency among those with comorbid PTSD and
SUD. A repeated measures ANOVA determined that the high baseline dysregulation group that
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received relapse prevention treatment showed no change in substance use frequency from
baseline to follow-up. Additionally, the high baseline dysregulation group that received
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
(COPE) showed a trending decrease in dysregulation at follow-up. Altogether, this exploratory
study provided evidence that exposure therapy can be tolerated by and beneficial to highly
dysregulated persons with both PTSD and SUD and that psychotherapy focusing only on
substance used may be contraindicated for highly dysregulated individuals with comorbid PTSD
and SUD.
Keywords: substance dependence, posttraumatic stress disorder, emotion dysregulation,
prolonged exposure
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CHAPTER 1: INTRODUCTION
Study Rationale
The absence or impairment of emotion regulation abilities characterizes many
psychological disorders of affect and thought. For instance, chronic worry and stress, avoidance
or restriction of emotions, abrupt shifts in emotions and moods, and inappropriate affect, are
among the symptoms of emotion dysregulation that define many clinical disorders (Cole, Michel,
& Teti, 1994). Research has implicated emotion dysregulation in posttraumatic stress disorder
(PTSD) and substance use disorders (SUDs; Savov & Atanassov, 2013; Schore, 2003). The
present study examined symptoms and features associated with high baseline emotion
dysregulation among a population with comorbid PTSD and SUD. Additionally, this research
explored the role of emotion dysregulation for treatment outcomes. Lastly, the study assessed
the mutability of emotion dysregulation among people with concurrent PTSD and SUD.
My interest in the area of emotion regulation arose from its critical role in adaptive
functioning in stressful environments. The ability to understand and modulate affective
responses to stress has been linked to emotional resilience and has been identified as a protective
factor against pathology (Allen & Fonagy, 2006). Examining the relationship between treatment
and emotion dysregulation will help to inform best practices relevant to clinical populations
struggling with deficits in the area of emotion regulation.
Study Aims
Emotion dysregulation is “inherent to many forms of psychopathology and may present
in extremes of either avoidance and overly restricted emotional expression or heightened
emotionality” (Bradley et al., 2011, p. 686). Emotion dysregulation is a multi-faceted construct
involving a lack of awareness, understanding, and acceptance of emotions; an inability to control
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behaviors when experiencing emotional distress; a lack of access to adaptive strategies for
modulating the intensity of emotional experiences; and an attempted avoidance of emotional
distress (Gratz & Roemer, 2004). Previous studies using non-clinical and community samples
found associations between PTSD symptom severity and overall emotion dysregulation (Weiss,
Tull, Anestis, & Gratz, 2013). Similar associations were observed among a treatment-seeking
cocaine dependent sample (McDermott, Tull, Gratz, Daughters, & Lejuez, 2009). This study
examined features associated with emotion dysregulation among a comorbid PTSD and SUD
population. This research examined correlations between baseline emotion dysregulation and
symptom severity (e.g., PTSD and substance dependence). It further sought to provide a more
complete understanding of the relationship between emotion dysregulation and psychopathology
among a comorbid PTSD and SUD population.
A comorbid PTSD and SUD diagnosis is associated with a range of negative clinical
outcomes including high risk for treatment dropout (Brady, Dansky, Back, Foa, & Carroll, 2001;
Ford, Hawke, Alessi, Ledgerwood, & Petry, 2007), relapse following SUD treatment (Hien,
Nunes, Levin, & Fraser, 2000; Najavits et al., 2007), more intense substance use patterns
(Najavits et al., 2007), and high rates of high risk and self-destructive behaviors (Najavits et al.,
2007). Despite these associations, few studies have examined psychological factors, such as
emotion dysregulation, associated with these negative clinical outcomes. This study examined
emotion dysregulation as a predictor for treatment outcomes.
Cognitive behavioral therapy (CBT) treatments are evidence-based interventions for
PTSD and SUD (Foa, Keane, Friedman, & Cohen, 2008; van Dam, Vedel, Ehring, &
Emmelkamp, 2012). Additionally, CBT has been shown to be effective for PTSD and SUD
together (Najavits, 2002). Some CBT treatments for comorbid PTSD and SUD, like relapse
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prevention therapy (RPT), do not directly address trauma-related symptoms but instead focus on
identifying high-risk use situations, bolstering coping strategies for managing relapse and
cravings, finding ways to maintain lifestyle balance, and establishing more adaptive ways of
responding to intense emotions. Other CBT treatments for comorbid PTSD and SUD, such as
Concurrent Treatment of PTSD and Substance Dependence Using Prolonged Exposure (COPE),
utilize an exposure technique to directly and experientially address emotion regulation problems
and associated physiological arousal through habituation in order to disrupt fear responses.
Some research suggests that this type of therapy may be helpful in the treatment of comorbid
populations (Mills et al., 2012). Exposure therapy aims to help individuals assimilate and
integrate their overwhelming experiences; addressing underlying dysregulation, which affects the
intensity of the PTSD symptoms, may in turn reduce substance use. This relationship between
PTSD and SUD is consistent with the concept of the self-medication hypothesis (Khantzian,
1997).
High levels of emotion dysregulation are common among individuals with comorbid
PTSD and SUD. Clinicians are often hesitant to use exposure therapy with this population for
fear that it is contraindicated and will lead to decompensation and/or dropout (van Minnen,
Harned, Zoellner, & Mills, 2012). Recent studies have challenged these assumptions and
demonstrated the appropriateness of exposure therapy for treating comorbid PTSD and SUD
(van Minnen et al., 2012). Patients in these studies did not get worse or demonstrate high rates
of relapse; instead, they demonstrated improvements with regards to both substance use and
PTSD outcomes (Brady et al., 2001; Mills et al., 2012; Najavits, Schmitz, Gotthardt, & Weiss,
2005; Triffleman, Carroll, & Kellogg, 1999). The extant research, however, is primarily limited
to small pilot studies, with only one large randomized controlled trial completed to date.
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Additional research is necessary both to examine the extent to which treatment impacts emotion
dysregulation among the comorbid PTSD and SUD population, and to determine the most
effective and appropriate treatments for this population.
The present study, using pre- and post-self-report measures, examined the change in
emotion regulation over time and explored the effects of baseline dysregulation on treatment
outcomes based on treatment type. Lastly, exclusive reliance on self-report measures of emotion
dysregulation is common among studies examining this psychological construct (e.g., Weiss et
al., 2013). Self-report responses may be influenced by the participant’s willingness or ability to
report accurately on emotional responses. Accordingly, in addition to self-report, this study
examined changes in emotion dysregulation over the course of a 12-week treatment using a
physiological arousal measure.
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CHAPTER 2: LITERATURE REVIEW
Overview
The present study examined the relationship between treatment type and change in
emotion regulation capacity in adults with comorbid PTSD and SUD, examining the effect of
baseline dysregulation on treatment outcomes. A literature review is presented in the next three
sections, beginning with an overview of emotion regulation, briefly summarizing developmental
and cognitive theoretical conceptualizations, and reviewing physiological mechanisms
underpinning emotion regulation and stress response. Additionally, emotion dysregulation
among traumatized and substance dependent populations respectively is discussed. Next, the
relationship between trauma and addiction is summarized, addressing the prevalence of PTSD
and SUD, and highlighting the pathways between PTSD and SUD. The literature on several
treatments that have been employed to effectively treat this comorbidity, such RPT and
exposure-based treatments, is summarized. Finally, literature on the use of exposure treatments
with highly dysregulated populations is reviewed, and the connection between emotion
dysregulation and acting-out behaviors is presented.
Emotion Regulation
Gross and Thompson (2007) aptly pointed out that the roots of contemporary research on
emotion regulation reside in the early study of psychological defenses, psychological stress and
coping, attachment theory, and emotion theory. Emotion regulation1 involves monitoring,
evaluating, and modifying internal feeling states and emotion-related physiological processes
(Eisenberg, Cumberland, & Spinrad, 1998). Ideal emotion regulation skills allow one to respond
1

This dissertation uses both the terms emotion regulation and emotion dysregulation. Emotion regulation is used
when referring to the successful monitoring, evaluating, and modifying internal feeling states and emotion-related
physiological processes. However, when emotion regulation is not successful, emotion dysregulation occurs, which
is by definition considered to be a dysfunctional state. This study was primarily focused on the mutability and
impact of emotion dysregulation.
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in flexible and appropriate ways (Cicchetti, Ganiban, & Barnett, 1991; Snyder, Schrepferman, &
St. Peter, 1997). Emotion regulatory processes may be automatic or controlled, conscious or
unconscious, and may dampen, intensify, or sustain emotions, depending on an individual’s
goals (Gross & Thompson, 2007). Various theorists have postulated different appraisal steps
used to assess internal or external situations; these appraisals modulate and give rise to emotional
responses.
Developmental Conceptualization of Emotion Regulation
Given the growing view that emotion regulation is a relational process, it follows
logically that its early development occurs in the attachment relationship (Fonagy, Gergely,
Jurist, & Target, 2002). Schore (2003) underscored that it is within the attachment relationship
that the primary caregiver shapes the development of the infant’s coping responses. Although
physiological, behavioral, and cognitive components clearly contribute to the emergence of
emotion regulation skills, external factors—such as early interactions with caregivers—and
direct methods of teaching children to behave in accordance with norms and expectations, also
influence emotion regulation (Cicchetti et al., 1991). Consequently, emotion regulation can be
viewed as an adaptive strategy that a child learns through interactions with the caregiving
environment to maintain the attachment relationship (Main & Solomon, 1990).
Describing it as instrumental in fostering the capacity for emotion regulation, Fonagy et
al. (2002) discussed affect mirroring, which they defined as the parent’s use of facial responses
and vocalizations to represent an understanding of the infant’s feeling states, and to be calming
rather than intensifying. In addition, they suggested that self-reflection and the ability to reflect
on the thoughts and feelings of others are capacities which are constructed, and have evolved
from the mother–infant relationship. When caregivers do not contingently respond to the
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infant’s affect, appropriate labeling of internal states does not occur, so that the affect remains
both confusing and unsymbolized, and ultimately difficult to regulate (Calkins, 1994). Through
repeated affect-mirroring experiences, the child begins to learn that his or her mental state is
decoupled from external reality. Maladaptive early experiences with caregivers impact later
development by limiting the ability to process or understand information related to mental states,
which is critical to adaptive functioning in a stressful environment.
Tronick (1989) emphasized the importance of the caregiver’s participation in interactive
repair, which occurs when the infant’s stress is regulated externally by dyadic exchanges.
Schore (1994) asserted that these micro-regulations lead to structural changes in the infant over
time. Schore (1994) referred to critical periods in the maturation of a child’s emotional system,
stating, “The outcome of effective dyadic affect regulatory transactions is an integration and
restructuring of the infant’s developing socioemotional system on a higher level of complexity”
(p. 32). By providing well-modulated affective stimulation, the caregiver facilitates the growth
of connections between cortical structures that neurobiologically mediate self-regulatory
functions (Schore, 1994). Early object relational experiences, thus, directly influence the
emergence of right-brain development and impact the ability to self-regulate emotional states
(Schore, 1994). Regions in the prefrontal cortex mature gradually into adolescence; thus, there
are periods in development when relational experiences organize reactivity and emotion
regulation.
Neurobiological Response and Emotion Regulation
Given the growing view that self-regulatory capacities have neurobiological correlates,
the next section of this review discusses the connection between neurobiological response and
emotion regulation. The hypothalamic-pituitary-adrenal (HPA) axis is central to the task of
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emotion regulation and stress response (Herman, Ostrander, Mueller, & Figueiredo, 2005). The
hypothalamus, hippocampus, and regions in the prefrontal cortex all play significant roles in
regulating the HPA axis. The HPA axis is a complex set of interactions between the
hypothalamus, the pituitary gland, and the adrenal glands.
In response to an acute or chronic stressor, the hypothalamus, a small gland at the base of
the brain serving as a regulatory center for body functions, releases corticotrophin-releasing
factor (CRF) into the bloodstream. The CRF travels, via blood vessels, to the pituitary gland, a
pea-sized structure located below the hypothalamus. In the anterior portion of the pituitary
gland, CRF stimulates the release of adrenocorticotropic hormone (ACTH). ACTH, in turn,
travels through the bloodstream from the pituitary gland to the two adrenal glands, located on top
of each kidney (Southwick, Ozbay, Charney, & McEwen, 2008). The outer portions of the
adrenals glands are stimulated by ACTH to release other hormones called glucorticoids such as
cortisol. The glucorticoids travel through the body as an adaptation to external stress. The rise
in glucorticoids prompts a cascade of reactions in the human body, including a rush of energy
and alertness. Glucorticoids like cortisol are also responsible for increasing blood sugar and
breaking down proteins and fats to help mobilize energy (Southwick et al., 2008).
Glucorticoids play an integral role in a negative feedback system to control the HPA’s
reaction to stress. If the stressor is mild, when glucorticoids reach the hypothalamus, further
excess release of CRF into the blood vessels is inhibited by hormones to a normal level. During
times of intense stress, the hypothalamus signals for more CRF release; the inhibitory
mechanism is overridden and the physiological stress reaction continues (Gunnar & Fisher,
2006).

9
Cognitive-Behavioral Conceptualization of Emotion Regulation
The limbic system, where the HPA axis is located, is the emotional center of the brain
and is responsible for the identification, processing, and memory of a feeling state. It is tasked
with determining next steps when an emotion is triggered (Hien, Litt, Cohen, Miele, &
Campbell, 2009). With this in mind, the next portion of this review will discuss cognitive
aspects of emotion regulation.
Contemporary cognitive-behavioral conceptualizations of emotion regulation emphasize
the role emotional arousal plays in adjusting decision-making processes, cueing behavioral
responses, and enhancing or distorting memory (Gross & Thompson, 2007). Emotions can be
detrimental as well as helpful, depending upon their timing and intensity. Emotion regulation
describes the processes by which individuals influence which emotions arise, when they arise,
and how emotions are experienced and expressed (Hien et al., 2009). The ability to achieve
goals, relate to others, and navigate life’s complexities depends upon the ability to appropriately
regulate emotions.
Emotion regulation was originally considered a demonstration of positive affect, but is
now recognized to be a balance of both positive and negative affect. In addition, as the concept
of emotion regulation has evolved over time, the importance of how much one regulates
emotions has diminished, and the importance of both the range of accessible emotional responses
and the degree to which a response appropriately matches a given situation has increased (Gross
& Munoz, 1995).
A subset of emotion regulation strategies is made up of the conscious cognitive
regulation processes. Cognitive emotion regulation can generally be described as the
management of emotionally activating or stressful information, with conscious cognitive
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strategies (Thompson, 1991). These cognitive processes are essential to the management of
stressful events, enabling the individual to manage and attempt to gain control over emotional
arousal (Zlomke & Hahn, 2010). Gross and Thompson (2007) described emotion regulation as
having five core processes: (1) situation selection, (2) situation modification, (3) attentional
deployment, (4) cognitive change, and (5) response modulation. Situational selection and
situational modification refer to both selecting and changing external situations to alter their
emotional impact.
Attentional deployment refers to the way in which individuals direct their attention in a
given situation to influence their emotions (Gross & Thompson, 2007). Two major attentional
deployment strategies are distraction and concentration. Distraction is the focusing of attention
on different aspects of a situation, or moving attention away from a situation altogether in an
effort to decrease arousal. Concentration is increasing the focus on the emotional features of a
situation.
Emotion requires that percepts be imbued with meaning and that individuals evaluate
their capacity to manage the situation (Gross & Thompson, 2007). Cognitive change refers to
altering how an individual perceives or appraises a situation, and adjusts the emotional
significance by changing either how he or she thinks about the situation or about the capacity to
manage the demands posed by the situation (Gross & Thompson, 2007). Cognitive reappraisal,
when used to down-regulate one’s negative emotional response, refers to the reframing of a
negative stimulus in less emotional terms (McRae, Ochsner, Mauss, Gabrieli, & Gross, 2008).
Response modulation refers to influencing physiological, experiential, or behavioral
responses. Attempts to regulate the physiological and experiential aspects of emotion are
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frequently referred to as suppression and are a result of an individual’s contextual assessment, as
well as implicit and explicit social and societal demands (Gross & Thompson, 2007).
In sum, research suggests that some combination of biological differences, environmental
influences, social factors, and cognitive processes affect emotion regulatory capacities. By
establishing an understanding of the mechanisms underlying differences in emotion regulatory
functions, the interrelated nature of the factors and their influence on each other is clearer.
Measurement of Emotion Dysregulation
Emotion dysregulation has been described as a multi-faceted construct. In turn, many
self-report instruments have been developed to measure various emotion regulation capacities
(for a comprehensive list of measures see Aldao, Nolen-Hoeksema, & Schweizemeta, 2010).
The Difficulties in Emotion Regulation Scale (DERS; Gratz & Roemer, 2004) represents the
most comprehensive measure of the construct to date and it exhibited good reliability and
validity in adults (Weinberg & Klonsky, 2009). The DERS was designed to measure the
complexities and clinically relevant difficulties of emotion regulation as described by several
theories of emotion regulation (Sloan & Kring, 2007).
On the one hand, because self-report measures are relatively easy and inexpensive to
administer, they are commonly used in research settings. On the other hand, the extent to which
individuals are able to accurately report their experiences of dysregulation has not been
confirmed (Tamir, Robinson, & Clore, 2002). The accuracy of self-report measures depends, at
least partially, on the participant’s insight, awareness, and capacity for metacognition (Cole,
Martin, & Dennis, 2004). Certain clinical populations, including traumatized populations, often
have a diminished capacity to identify and label their emotional experiences which further
complicates the utility of self-report measures.
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Alternatively, researchers have utilized observational methods to study emotion
regulation, usually by instructing participants to engage in an emotion-eliciting stimulus and then
observing the resultant emotions, cognitions, and physiological responses (e.g., NolenHoeksema, Wisco, & Lyubomirsky, 2008). With increasing popularity, physiological measures
of autonomic activity have been used as markers of emotional arousal. These measures of
emotional arousal include electrodermal skin conductance, blood pressure, finger pulse, ocular
startle reflex, pupil diameter, and heart rate (Bradley, Miccoli, Escrig, & Lang, 2008; Gross,
2002). Specifically, the present study used a skin conductance measure to detect rapid
fluctuations in sweat gland activity in response to the sympathetic nervous system (Boucsein,
1992); these fluctuations indicate changes in arousal and are markers for dysregulation. A case
illustration utilizing skin conductance data will be presented.
The Impact of Trauma Upon Emotion Regulation
One of the components of emotion dysregulation is a tendency for emotions to quickly
escalate and change rapidly, be expressed in unmodified forms, and overwhelm both coping
capacity and reasoning (Bradley et al., 2011). Developmental research suggests that selfregulatory deficits result from an interaction of several factors, including temperamental and
biological variables, as well as intrusive, chaotic, and stressful early life experiences, including
abuse, neglect, and problematic attachment relationships (Schore, 1994, 2003). Emotion
regulation skills allow for flexible and appropriate responses to stress and are essential to the
development of many capacities, including optimal interpersonal functioning (Calkins, 1994;
Cicchetti et al., 1991). Schore (2003) suggested that early life trauma, relational abuse, or
dysregulated attachment systems can produce specific patterns of neurobiological alterations.
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Chronic early traumatic stress can disrupt maturing emotion regulation functions and increase the
risk of lifelong deficits in this area (Teicher, 2000).
Some of the neurobiological alterations include the suboptimal functioning of the HPA
axis. The literature posits that glucorticoids act through two types of receptors participating in
the stress response. Type I maintains the capacity of the brain to respond to conditions that
potentially threaten the organism. Type II counteracts the impact of the other stress processes
and returns the organism to pre-stress levels of functioning (Gunnar & Fisher, 2006). Normally,
the feedback loop allows the body to disable these defenses when the threat passes. But in some
cases, cortisol levels rise too often, or stay elevated too long (Gunnar & Fisher, 2006). When the
HPA axis is overactive, as in the case of chronic arousal, the negative feedback loop becomes
progressively weaker (Gunnar & Fisher, 2006). Repeated patterns of intense emotional
experiences, like trauma exposure, may then lead to chronic changes in emotional sensitivity
levels.
The HPA axis functions in concert with several other neural pathways. HPA
dysfunctions are thought to likely to be associated with impaired integration of information from
the amygdala, hippocampus, and prefrontal cortex (Herman et al., 2005). Research in this area
seems to indicate that a suboptimally functioning HPA axis may be either hypo-responsive or
hyper-responsive, affecting the functioning of the sympathetic and parasympathetic nervous
systems (Gunnar & Fisher, 2006). Although this body of research is still not well developed, the
hypothesized links between childhood trauma and neurobiological consequences are thought to
involve over-programming of neurotransmitters impacting the stress response. These irregular
neurochemical responses are hypothesized to be detrimental to the brain during critical stages of
development (Teicher, 2002). Neurobiological research on trauma and the stress response seem
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to evidence that neurobiological changes in major structures in the limbic system lead to
dysregulation of arousal systems (Schore, 2003).
Emotion Dysregulation Among Substance Dependent Populations
Khantzian (1997, 2003) posited that substance users have difficulty tolerating negative
emotions and managing overwhelming emotional states, and tend to use substances to achieve
emotional stability. Khantzian and others have also asserted that substance abusers have not
developed adaptive defensive mechanisms to deal with rage and aggression (Duncan, 1975;
Glover, 1932; Khantzian, 2003; Radó, 1933). Aharonovich, Nguyen, and Nunes’s (2001) study
examining levels of aggression and depression among individuals with SUDs, found higher
levels of psychological distress in substance abusers than a non-clinical sample group. A study
examining the capacity for emotion comprehension and emotion management found that
individuals with SUDs scored lower on these dimensions than a non-clinical control group
(Hertel, Schutz, & Lammers, 2009). Hien and Miele (2003) found that emotion-focused coping
style mediates the relationship between substance use and aggressive behavior. Together, these
findings suggest that underlying emotion dysregulation contributes to an understanding of
antisocial and aggressive behavior in this population. These results support the theoretical
literature which suggests that individuals who abuse substances and exhibit aggressive behavior
are likely to have emotion regulation deficits.
Emotion dysregulation and poor emotional coping skills have been identified as a risk
factor for substance abuse disorders (Cooper, Frone, Russell, & Mudar, 1995; Thorberg &
Lyvers, 2006). Additionally, a recent meta-analysis implicated high negative affect, low positive
affect, and low effortful control in the initiation and maintenance of SUDs (Cheetham, Allen,
Yucel, & Lubman, 2010). Among individuals with SUDs, negative mood states have been
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shown to induce cravings (Childress et al., 1994). Research examining neurobiological
substrates underlying SUDs highlight the dysregulation of brain reward and stress systems
among this population (Cheetham et al., 2010; Koob, 2003). In turn, individuals may use drugs
or alcohol in an attempt to lessen the biological effects of a dysregulated stress response system.
In sum, developmental research suggests that self-regulatory deficits result from an
interaction of several factors, including temperamental and biological variables, as well as
traumatic life experiences, including abuse, neglect, and problematic attachment relationships
(Schore, 1994, 2003). Schore (2003) suggested that early life trauma, relational abuse, or
dysregulated attachment systems can produce specific patterns of neurobiological alterations.
Neurobiological research on trauma and the stress response suggest that neurobiological changes
lead to dysregulation of arousal systems (Schore, 2003). Additionally, dysregulation and poor
emotional coping skills have been identified as a risk factor for substance abuse disorders.
Empirical and theoretical literature suggests that individuals who abuse substances and are likely
to have emotion regulation deficits. In conclusion, emotional dysregulation is a shared feature of
both trauma and addiction.
Trauma and Addiction
While comorbid individuals are often excluded from treatment research, all persons
included in this study met criteria for both PTSD and SUD. The following section will present
the diagnostic criteria relevant to the clinical population under investigation. Additionally,
epidemiological data will be summarized, presenting the prevalence and incidence of SUD and
PTSD in the population. Lastly, the pathways between SUD and PTSD will be presented and the
hypothesized underlying mechanisms relating the two conditions will be discussed, highlighting
the ways that emotional dysregulation is relevant to the co-occurring disorders.
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PTSD is a syndrome marked by the development of symptoms of intense horror or fear
following a psychologically distressing event involving a real or perceived threat to physical
well-being. This disorder typically results from an extreme, catastrophic, or overwhelming realworld experience and is typically accompanied by the following symptoms: re-experiencing the
event through flashbacks, nightmares, and intrusive memories; avoidance of stimuli associated
with the event; and increased arousal (American Psychiatric Association [APA], 2000).
The Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM-IVTR; APA, 2000) provides diagnostic criteria for two forms of SUDs: substance abuse and
substance dependence. Substance abuse is characterized by a maladaptive pattern of use of a
substance leading to clinically significant impairment or distress. Maladaptive use is described
as the repetition of at least one of the following: use in physically hazardous situations,
substance-related legal problems, failure to fulfill major obligations, or interpersonal problems
related to substance use. Substance dependence, too, is a maladaptive pattern of use that is
characterized by three or more of the following conditions: increased tolerance of the substance;
onset of withdrawal symptoms; using larger quantities of a substance, increased frequency of
substance use or use for a longer period of time than was planned; unsuccessful efforts to reduce
or regulate use; significant time spent procuring, using, or recuperating from use; disruption of
important social, occupational, or recreational activities; and continued use despite recognizing
its negative impact on a physical or psychological well-being (APA, 2000).
This study utilized the DSM-IV-TR for diagnostic purposes; the DSM-5 (APA, 2013),
however, has since been published. The DSM-5 criteria for SUD are nearly identical to the
DSM-IV-TR substance abuse and dependence criteria combined into a single list. However, the
threshold for a SUD diagnosis in DSM-5 is held at two or more criteria, in contrast to a threshold
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of one or more criteria for a diagnosis of DSM-IV-TR substance abuse and three or more for
DSM-IV-TR substance dependence. Additionally, the PTSD diagnostic criteria have changed
slightly. The stressor criterion (Criterion A) is more explicit about the experienced “traumatic”
events. Furthermore, there were three major symptom clusters in DSM-IV-TR (re-experiencing,
avoidance/numbing, and arousal). In the DSM-5, there are four symptom clusters; the
avoidance/numbing cluster is divided into two distinct clusters: avoidance and persistent
negative alterations in cognitions and mood. Because the criteria changes for these disorders
were relatively minor, the findings from this study are likely generalizable to persons with
comorbid PTSD and SUD as classified by the newer manual.
A few large-scale epidemiological studies have been conducted among the general
population to assess the prevalence of PTSD and SUDs. One study indicated a 6.4% lifetime
prevalence of PTSD and a 35.3% lifetime prevalence of SUDs (Kessler, Sonnega, Bromet,
Hughes, & Nelson, 1995). A second and more recent epidemiological study also estimated the
lifetime prevalence of PTSD to be 6.4% (Pietrzak, Goldtein, Southwick, & Grant, 2011).
Among individuals with PTSD, approximately 46% met criteria for SUD.
The prevalence of comorbid PTSD and SUD can be examined in several ways. One
approach is to study the frequency of PTSD among those presenting with SUD, or conversely,
the frequency of SUDs in those presenting with PTSD. Among treatment-seeking samples, rates
of comorbid PTSD and SUDs are high. Individuals with PTSD were found to be up to 14 times
more likely than patients without PTSD to have a SUD (Chilcoat & Menard, 2003; Ford, Russo,
& Mallon, 2007). According to current literature, prevalence estimates for PTSD in SUD
samples vary from 11% to 41% (Harrington & Newman, 2007; Ouimette, Goodwin, & Brown,
2006; van Dam, Ehring, Vedel, & Emmelkamp, 2010). Additionally, patients with comorbid
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SUD and PTSD show higher symptom severities and worse treatment outcomes compared to
patients with either disorder alone (van Dam et al., 2012).
Although there is a well-established association between PTSD and SUD, the precise
underlying mechanisms that relate the two conditions are unclear. Three pathways have been
hypothesized. One, the high risk hypothesis, proposes that substance abuse leads to a higher risk
for exposure to traumatic experiences, thereby increasing the opportunity for developing PTSD
(Hien, Cohen, & Campbell, 2005). A second, the susceptibility hypothesis, proposes that
concurrent PTSD and SUD are due to an underlying, biological vulnerability, increasing the risk
for developing both disorders independently following exposure to a trauma (Stewart & Conrod,
2002). Lastly, the self-medication hypothesis, posits that individuals with trauma histories and
related PTSD frequently use substances in an effort to manage or avoid distressing symptoms
and to relieve painful emotions or physical sensations associated with their traumas (Khantzian,
1997; Stewart & Conrod, 2002).
To date, the self-medication hypothesis is the only causal model with empirical support
(Stewart & Conrod, 2002). Chilcoat and Breslau (1998) conducted a study testing causal
pathways between PTSD and SUD in a sample of 1,007 young adults. Using a prospective
design and analytical strategies testing for causal inference, the study was able to expound upon
findings from cross-sectional design studies. Support was only observed for only the selfmedication hypothesis.
Additionally, Hien, Jiang et al. (2010) conducted a study examining the temporal course
of improvement in PTSD and SUD symptoms among women in outpatient substance abuse
treatment. They found that PTSD symptom severity reductions were more likely to be
associated with a reduction in substance use. Their analysis showed minimal evidence of
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substance use symptom reduction improving PTSD symptoms. Results support the selfmedication model, using substances to cope with PTSD symptoms.
Additionally, underlying emotion regulation deficits have been associated with the
initiation and maintenance of SUD and may play an important mediating role between trauma
exposure and subsequent substance abuse (Horowitz, Overton, Rosenstein, & Steidl, 1992; Suh,
Ruffins, Robins, Albanese, & Khantzian, 2008). Addiction literature suggests that emotion
regulation deficits, including low tolerance for painful feelings and inability to self-soothe, are
typical of substance abusers (Cheetham et al., 2010). Krystal and Raskin (1970) proposed that
because difficult emotions often remain somaticized, and unverbalized among substance abusers,
people abusing substances are left ill-equipped to deal with their feelings. Self-medicating with
alcohol and drugs can provide temporary relief from the hyperarousal and numbing symptoms,
the dysregulated feeling states that are characteristic of PTSD (Hien et al., 2009). Though
substance use may result in the short-term reduction of PTSD-related symptoms and attendant
emotional distress, it is likely to have paradoxical consequences in the long term (Weiss et al.,
2013). Substance use is theorized to prevent exposure to or awareness of corrective information
and interfere with emotional processing (Foa & Kozak, 1986). Thus, using substances to
regulate emotions may exacerbate and prolong PTSD symptoms and emotion dysregulation in
the long term, increasing motivations to use substances as an avoidant regulation strategy
(Hayes, Wilson, Gifford, Follette, & Strosahl, 1996).
Treatments for Comorbid PTSD and SUD
The developmental and cognitive theoretical conceptualizations as well as the
physiological mechanisms underpinning emotion dysregulation have been outlined above. The
ability to modify emotions in a desired direction and to accept and tolerate undesired emotions is
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requisite for optimal mental health. Emotion regulation deficits common among traumatized and
substance dependent populations have been implicated in the initiation and maintenance of
comorbid PTSD and SUD. Treatments for these complex comorbid problems utilize a variety of
approaches. However, to date, few studies have examined the effect of the various available
treatments on emotion dysregulation in this population. Additionally, there is a paucity of
research which examines the effect of emotion dysregulation on treatment efficacy. The present
study will examine correlations between baseline emotion dysregulation and symptom severity,
establish emotion dysregulation as a predictor for treatment outcomes, examine the extent to
which treatment impacts emotion dysregulation among a comorbid PTSD and SUD population,
and examine changes in emotion dysregulation over the course treatment.
Clinical interventions for comorbid PTSD and SUD can be divided into two broad types:
those which utilize prolonged exposure techniques (often also called present-focused or traumafocused) and those that do not. Exposure therapy, directly and experientially, addresses emotion
dysregulation problems and associated physiological arousal through habituation to disrupted
fear responses. The second type of treatment for comorbid PTSD and SUD focuses mainly on
skills training, building coping strategies to manage overwhelming situations and emotions.
While exposure therapy is currently considered one of the treatments of choice for PTSD alone
(van Minnen et al., 2012), there is little consensus in the literature regarding the appropriateness
of exposure therapy for highly dysregulated and comorbid PTSD and SUD populations. With an
eye toward the role of emotion dysregulation, the next section of this literature review provides a
summary of clinical interventions used to address dysregulation and symptomatology associated
with the comorbid PTSD and SUD population.
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Skills training treatments include interventions such as Seeking Safety (Najavits, 2002),
CBT for PTSD in SUD treatment (McGovern et al., 2009), Substance Dependence PTSD therapy
(Triffleman, Carroll, & Kellogg, 1999), Transcend (Donovan, Padin-Rivera, Kowaliw, 2001),
and RPT (as described in Carroll, 1996). The skill-training treatments are divided into
integrative treatments, those that focus on PTSD and SUD simultaneously, and sequential
treatments, those that treat the disorders one at a time. The standard mode of care for comorbid
PTSD and SUD in many substance abuse treatment programs is to treat the SUD first and to
defer treatment of trauma-related issues. The clinical rationale behind deferring trauma
treatment relates to a fear of that unaddressed substance abuse could impede other therapeutic
efforts and potentially cause relapse (Pitman et al., 1991). The integrated model of treatment for
comorbid PTSD and SUD requires that both disorders both be targeted simultaneously
throughout the treatment. The integrated model posits that addressing trauma early in a
treatment and providing concurrent relief form PTSD symptoms improves recovery from SUDs
(Back, 2010; Hien, Campbell, Ruglass, Hu, & Killeen, 2010).
Hien, Cohen, Miele, Litt, and Capstick (2004) compared two skills training CBT
treatments, Seeking Safety, a gold standard integrative treatment for PTSD and SUD and RPT
with comorbid PTSD and SUDs. RPT impacted both PTSD and SUD symptoms as effectively
as Seeking Safety, the integrated treatment. It is hypothesized that the skills gained through RPT
generalized to PTSD-related difficulties including, for example, issues of self-care, safety,
depression, and anxiety without direct emphasis on trauma in the treatment. Overall, findings
provided evidence that RPT is an efficacious, short-term treatment for comorbid PTSD and SUD
symptoms. While it was not measured, Hien et al. (2004) suggested that both Seeking Safety
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and RPT may positively alter the emotion regulation capacities of individuals with comorbid
PTSD and SUD.
Alternatively, several approaches to treatments for comorbid PTSD and SUD utilize a
two-pronged strategy, employing both skill training and exposure-based therapy simultaneously.
These types of interventions include Seeking Safety plus Exposure Therapy-Revised (Najavits et
al., 2005), Concurrent Treatment of PTSD and Cocaine Dependence (Back, Dansky, Carroll,
Foa, & Brady, 2001) and COPE (Mills et al., 2012). Experts in the field of substance abuse
treatment, however, have historically been hesitant to use prolonged exposure to treat individuals
with comorbid PTSD and SUD. The exposure-based behavioral therapies, particularly those that
involve imaginal re-experiencing of trauma, were suspected to be contraindicated for people with
addictions, for fear of relapse, treatment dropout, increased acting-out behaviors, and
dysregulation (van Minnen et al., 2012). In sum, prolonged exposure was considered
inappropriate for use among patients with SUD as it was believed that these patients would be
unable to cope with the intense emotions triggered during exposure, placing them at increased
risk for relapse (Foa & Rothbaum, 1998).
Acting-out behaviors can represent an attempt to cope with triggered or sustained
posttraumatic emotional states, especially when these states overwhelm emotion regulation
capacities (van der Kolk et al., 1996). Interpersonal trauma may especially activate acting-out
behaviors because it produces heightened negative emotional states and disrupts the biological
and psychological aspects of emotional regulation that ordinarily serve to regulate intense
emotion (Pearlman & Courtois, 2005). Briere, Hodge, and Godbout (2010) conducted a study
examining the relationship between interpersonal trauma, PTSD, emotion dysregulation, and
acting-out behaviors. Their findings suggested that level of PTSD symptomatology alone does
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not predict acting-out behaviors. Instead such behaviors are triggered and reinforced by reduced
emotion regulation capacity (Briere et al., 2010). The relationship between acting-out behaviors
and emotion regulation capacity reinforced concerns that PTSD treatments involving prolonged
exposure may prove to be too activating for individuals who have a particular difficulty downregulating heightened negative emotional states.
Alternatively, a recent empirical study examining the impact of dysregulation on the
efficacy of prolonged exposure suggested that patients presenting with severe dissociative
symptoms profit similarly from exposure treatment as do patients with minimal dissociative
symptoms (Hagenaars, van Minnen, & Hoogduin, 2010). The findings from this study challenge
the assumed contraindication of employing prolonged exposure with dysregulated populations.
Until recently, prolonged exposure was considered theoretically inappropriate for use
among patients with substance dependence (van Minnen et al., 2012). It was widely believed
that these dually diagnosed individuals would have difficulty coping with the intense emotional
activation elicited by exposure therapy (Killeen, Back, & Brady, 2011). Recently, the field’s
skepticism has begun to be empirically addressed (Mills et al., 2012). To date, existing research
is primarily limited to smaller pilot studies (Brady et al., 2001; Coffey, Stasiewicz, Hughes, &
Brimo, 2006; Triffleman et al., 1999). Recently, however, one large randomized control trial
evaluating the efficacy of prolonged exposure therapy for individuals with PTSD and SUD was
conducted (Mills et al., 2012).
The Mills et al. (2012) randomized control trial (N = 103) compared COPE plus usual
treatment with usual treatment for substance dependence. COPE consisted of 13 individual 90minute sessions with a clinical psychologist and usual treatment included any type of substance
use treatment available in the community. From baseline to 9-month follow-up, the combined
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use of COPE plus usual treatment resulted in a significant improvement in PTSD symptom
severity as compared to usual treatment. Both treatment groups demonstrated significant
reductions in severity of substance dependence, substance use, depression, and anxiety; however,
the difference between groups was not significant.
Despite exposure therapy’s promise and significant efficacy in treating PTSD, the main
clinical concern, which has likely limited the wider application of this techniques in comorbid
PTSD and SUD populations, is tolerability. The Mills et al. (2012) COPE study revealed that
exposure did not worsen patients’ symptoms and in fact it significantly improved PTSD,
substance use, and general psychiatric symptoms among treatment completers. Emotion
dysregulation appears to be a fundamental aspect of both trauma and addiction. Treatments
targeted to address this type of outcome have yet to examine (1) emotion dysregulation as a
predictor for treatment outcomes, (2) the extent to which treatment impacts emotion
dysregulation among a comorbid PTSD and SUD population, and 3) changes in emotion
dysregulation over the course treatment. The present study will provide additional empirical data
to further inform the field about safe and efficacious treatments for this difficult-to-treat
population.
Study Aims and Research Questions
PTSD and SUD are frequently comorbid with prevalence estimates varying from 11 to
41% (van Dam et al., 2010). Because comorbid PTSD and SUD is associated with poorer
psychological treatment outcomes, and increased service utilization than either disorder alone,
comorbid PTSD and SUD remains a serious public health concern. Given the high prevalence of
PTSD and SUD comorbidity, it is important to further understand the underlying mechanisms of
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the disorders and to develop and evaluate treatment approaches appropriate for this vulnerable
population.
Trauma has been shown to disrupt self-regulatory processes; emotion regulation deficits
have also been implicated in the initiation and maintenance of SUDs (Hien et al., 2005). In sum,
emotion dysregulation is a shared feature of both PTSD and SUD. Treatments for these complex
comorbid problems utilize a variety of approaches. However, to date, few studies have
examined the effect of the various available treatments on emotion dysregulation in this
population.
In conclusion, this study aimed to extend the research on emotion dysregulation among
the comorbid PTSD and SUD population. It examined features associated with emotion
dysregulation, correlating dysregulation with myriad symptoms affecting this clinical population.
Specifically, the study focused on baseline emotion dysregulation as a predictor of treatment
outcomes. The overall study offered three exploratory research questions.
Rationale for Research Question 1
Emotion dysregulation is inherent to many forms of psychopathology (Bradley et al.,
2011). It is a multifaceted construct involving a lack of awareness, understanding, and
acceptance of emotions; an inability to control behaviors when experiencing distress; a lack of
access to adaptive strategies for modulating the intensity of emotional experiences; and an
attempted avoidance of emotional distress (Gratz & Roemer, 2004). Previous studies using nonclinical and community samples found associations between PTSD symptom severity and overall
emotion dysregulation (Weiss et al., 2013). Similar associations were observed among a
treatment-seeking cocaine dependent sample (McDermott et al., 2009). This study will examine
features associated with emotion dysregulation among a comorbid PTSD and SUD population.
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Specifically, the first research question will examine diagnostic features associated with emotion
dysregulation at baseline.
Research Question 1. Will there be a relationship between baseline emotion
dysregulation, as measured by the DERS, and baseline symptoms of PTSD and SUD, as
measured by the Clinician-Administered PTSD Scale (CAPS) and Timeline Follow Back
(TLFB)?
Rationale for Research Question 2
From a neurobiological perspective, several parts of the brain have been implicated in
emotion regulation processes. In particular, structures in the limbic system have been shown to
play a role in learned emotional associations that become automatic over time (i.e., bottom-up
processes). Other structures in the brain, particularly areas located in the frontal lobes, have been
implicated in the regulation of emotion (i.e., top-down processes). Exposure-focused treatments
and skills-based treatments are premised on different understandings of emotion dysregulation.
RPT aims to change behavior through a top-down approach, examining cognitions in relation to
affect. COPE, the only exposure treatment developed to treat SUD, utilizes a bottom-up fear
habituation processing approach. Specifically, the second research question explored whether
baseline emotion dysregulation is a predictor for treatment outcomes.
Research Question 2. Will treatment type moderate the relationship between baseline
dysregulation, as measured by the DERS, and treatment outcomes, as measured by the CAPS
and substance use days in the last 7 at follow-up?
Rationale for Research Question 3
To the extent that certain emotion regulatory strategies are theorized to be more adaptive
than others, it can be hypothesized that psychologically based treatments may affect emotion
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regulatory capacities. Empirical evidence that treatment, in fact, alters emotion regulation is
currently sparse. Demonstrating how emotion regulation is changed by therapy is an important
avenue for future research.
Because self-report measures are relatively easy and inexpensive to administer, they are
commonly used in research settings. The accuracy of self-report measures depends, at least
partially, on the participant’s insight, awareness, and capacity for metacognition (Cole et al.,
2004). Certain clinical populations, including traumatized populations, often have a diminished
capacity to identify and label their emotional experiences which further complicates the
usefulness of self-report measures.
Alternatively, researchers have used observational methods to study emotion regulation,
usually by instructing participants to engage in an emotion-eliciting stimulus and then observing
the resultant emotions, cognitions, and physiological responses. Despite compelling reasons to
use multiple methods to assess emotion dysregulation, few studies have done so. This study
however, used a skin conductance measure to detect rapid fluctuations in sweat gland activity in
response to the release of acetylcholine by the sympathetic nervous system (Boucsein, 1992);
these fluctuations indicate changes in arousal.
Specifically, the third research question examined change in emotion dysregulation preand post-intervention as well as over the course of treatment.
Research Question 3. Will treatment type moderate the relationship between baseline
dysregulation, as measured by the DERS, and emotion dysregulation at follow-up, as measured
by DERS total score at follow-up and physiological arousal over the course of a 12-week
treatment?
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CHAPTER 3: METHOD
Study Design
This dissertation research is a secondary analysis of part of the data from a randomized
clinical trial assessing the relative efficacy of two active treatment conditions for substance
dependent individuals who also met criteria for current DSM-IV-TR PTSD. Eligible participants
(see inclusion and exclusion criteria below) were randomly assigned to: (1) COPE, (2) RPT, or
(3) delayed treatment. The study was a three-armed randomized controlled trial with repeated
outcome measures at baseline; post treatment; and 1, 2, and 3 months post-treatment. Trained
therapists administered the behavioral interventions on an individual basis for 12 one-hour
weekly sessions.
This 2 × 2 pre-post control group design study examined the correlation between baseline
emotion dysregulation (as measured by the DERS, a self-report measure) and symptom severity
at baseline (as measured by the Clinician-Administered PTSD Scale and the Timeline Follow
Back). Secondly, the study examined baseline emotion dysregulation as a predictor for treatment
outcomes (as measured by the Clinician-Administered PTSD Scale and the Timeline Follow
Back) to identify differences in the predictive power of baseline dysregulation based on
treatment type (i.e., RPT or COPE). Thirdly, the study assessed longitudinal changes in emotion
dysregulation over time (at baseline and at 1 week post-treatment), examining a relationship
between change in emotion dysregulation (as measured by the DERS) and treatment type (i.e.,
RPT or COPE). Lastly, we examined longitudinally changes in emotion dysregulation (as
measured by physiological arousal) over the course of a 12-week treatment.
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Procedure
Sample
Individuals referred from the Addiction Institute of New York, and the Women’s Health
Project Treatment Research Center, as well as participants referred from other sources, including
those responding to advertisements in the local papers and on Craigslist were screened. A total
of 80 men and women were randomized into treatment conditions.
Eligible participants were between 18 and 65 years of age and able to comprehend
English. All participants met DSM-IV-TR criteria for current drug or alcohol dependence and
used illicit substances within the past 3 months. Participants also met DSM-IV-TR criteria for
current PTSD in response to an interpersonal trauma. Participants all provided informed consent
and understood all assessment instruments. Participants all provided the name of at least one
person who would know where to contact them if they were to move or change phone numbers.
Participants were willing to commit to 12 therapy sessions and five research assessment
interviews.
Participants were deemed ineligible if they had a history of or current psychotic,
schizoaffective, bipolar, eating, or dissociative identity disorder. These individuals were not
considered psychiatrically stable enough to tolerate or benefit from the proposed treatment.
Participants, however, with other psychiatric disorders, including mood or anxiety disorders,
were included, due to the high frequency of comorbid psychiatric disorders among patients with
PTSD (Brady, Killeen, Saladen, Dansky, & Becker, 1994). Additionally, participants who
presented a serious homicide or suicide risk or were involved in a violent intimate partnership
(perpetrator or victim) were ineligible for the study. Participants already receiving PTSDspecific treatment or those on antidepressants, mood stabilizing medications, or methadone—
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initiated during the less than 8 weeks prior to study participation—were excluded from the study.
Lastly, individuals with organic mental syndrome as indicated by a score of less than or equal to
21 on the Mini-Mental Status Exam were not eligible for the study.
Behavioral Interventions
Cognitive-Behavioral Therapy in Conjunction with Prolonged Exposure (COPE).
COPE is a manualized 12-week intervention, using cognitive-behavioral strategies and
prolonged exposure techniques to decrease PTSD and SUD symptoms in individuals with
concurrent PTSD and substance dependence. COPE represents a combination of empirically
validated and efficacious cognitive-behavioral treatments for substance dependence and PTSD
(Carroll, Nich, & Rounsaville, 1998; Foa & Rothbaum, 1998). In COPE, patients receive
psychoeducation pertaining to the underlying principles of cognitive and exposure-based
therapies in addition to the interrelatedness of PTSD and substance dependence. Coping skills
training, relapse prevention techniques, and cognitive restructuring are taught to reduce
substance use severity. In-vivo and imaginal exposure therapy techniques are used to reduce
PTSD symptom severity. The primary goals of COPE are to (1) educate patients about the
relationship between substance dependence and PTSD, (2) initiate and maintain abstinence, and
(3) reduce PTSD symptom severity.
Relapse prevention treatment (RPT). RPT is a widely used cognitive-behavioral skills
training designed to initiate and maintain abstinence from various types of substance (Carroll,
Rounsaville, & Gawin, 1991; Rawson, Obert, McCann, & Marinelli-Casey, 1993). The RPT
model is based on the concept that the same cognitive, behavioral, and affective mechanisms
underlie all processes of relapse, regardless of the actual problem behavior (Marlatt & Gordon,
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1985). By using RPT as a comparison intervention, it was possible to examine the specific
effects of exposure therapy integrated into a CBT platform.
In general, RPT consists of the following elements: (1) psychoeducation about the
biological, psychological, and social effects of addiction to and recovery from various
substances; (2) identification of high-risk situations for and early signs of relapse; (3)
development of coping skills for achieving abstinence—especially refusal and avoidance skills,
behavioral skills for substituting drug use with drug-free behaviors in high risk situations,
cognitive skills for overcoming cravings, drug-free stress management skills, and affective skills
for labeling and expressing emotions without drugs; (4) increasing perceived self-efficacy to
achieve and maintain abstinence; (5) development of cognitive and behavioral skills for
preventing the abstinence violation effect; and (6) development of drug-free lifestyle behaviors.
Measurement
Demographic Measures
Demographic and Treatment History Form (DEMO). The DEMO is a structured 62item social and treatment history interview designed to provide basic demographic and life
history information related to the course of illness, including: demographic variables, family
history, age of onset of substance and/or psychiatric problems, history of hospitalizations,
previous treatment, symptoms, and diagnoses (Hien & Zimberg, 1991). The measure was
administered five times: at baseline; immediately post-12-week intervention; and 1, 2, and 3
months post-treatment.
Any baseline variables including age, age of onset of psychiatric and SUDs, symptom
severity, other DSM-IV-TR diagnoses, and trauma-related characteristics (e.g., type of trauma,
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age at which first trauma occurred)—which significantly differed across study arms—were
treated as covariates and controlled for in the analyses.
Trauma Symptoms Measure
Clinician-Administered PTSD Scale (CAPS). The CAPS is a structured, clinical
interview for assessing the cardinal and hypothesized frequency and intensity of signs and
symptoms of PTSD. The CAPS measures DSM-IV-TR symptoms of PTSD, associated
symptoms of PTSD, validity of responses, impairments in social and occupational functioning,
and overall symptom severity. It also measures the degree of improvements since an earlier
rating. The CAPS has demonstrated strong convergent validity with the Structured Clinical
Interview for DSM-IV (SCID)–PTSD module
(r = .83) and the PTSD Symptom Scale Interview (r = .73; Foa & Tolin, 2000). The CAPS has
also been found to have sound psychometric properties; test–retest reliabilities ranged from .77
to .96 for the three symptom clusters and from .90 to .98 for the 17-item core symptom scale
(Blake et al., 1995). The measure was administered five times: at baseline; immediately post-12week intervention; and 1, 2, and 3 months post-treatment.
Substance Use Measure
Time Line Follow Back (TLFB). The TLFB is a clinician-assisted measure to assess
recent drinking behavior over the 90-day period prior to the interview. Subjects retrospectively
estimate their daily alcohol consumption while referencing a detailed calendar. The participant
is oriented to specific episodes of regular, erratic, or binge drinking by the clinician. The TLFB
is reliable and, in several studies, data obtained with a method like the TLFB have been sensitive
to changes in alcohol consumption. The TLFB has high temporal stability with most test–retest
correlations exceeding .85 (Sobell & Sobell, 1995). The TLFB was used to assess alcohol and
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drug use patterns 90 days prior to treatment; it was then administered at each follow-up point
(Sobell & Sobell, 1992, 1995, 2000). The measure was administered five times: at baseline;
immediately post-12-week intervention; and 1, 2, and 3 months post-treatment.
Emotion Regulation Measure
Difficulties in Emotion Regulation Scale (DERS). The DERS is a 41-item self-report
measure developed to assess clinically significant difficulties in emotion regulation. DERS
items were chosen to reflect difficulties within the following dimensions of emotion regulation:
(a) awareness and understanding of emotions; (b) acceptance and emotions; (c) the ability to
engage in goal-directed behavior, and refrain from impulsive behavior when experiencing
negative emotions; and (d) access to emotion regulation strategies perceived as effective.
Responses range from 1 to 5, with higher scores indicating greater difficulties in emotion
regulation. The total DERS was found to have good test–retest reliability (r = .88) and high
internal consistency (α = .93); the subscales also had high internal consistency (i.e., Cronbach’s α
> .80 for each). Preliminary findings suggest adequate construct and predictive validity (Gratz &
Roemer, 2004; Sloan & Kring, 2007). The measure was administered five times: at baseline;
immediately post-12-week intervention; and 1, 2, and 3 months post-treatment.
Physiological Arousal Measure
Electrodermal skin fluctuation. Electrodermal skin fluctuation is an instrument
commonly used in psychophysiology experiments to infer emotional state and cortical arousal
(Ressler et al., 2004; Storm et al., 2002). This methodology measures electrical conductance in
the skin through detecting variance in sweat gland activity. Because sweat glands become more
active in association with the arousal, a higher number and amplitude of conductance
fluctuations is thus correlated with heightened levels of stress (Storm, 2008). Using this
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physiological methodology to measure regulation of emotion strengthens the validity of selfreport emotion regulation findings.
The study utilized the ProComp2 electrodermal skin fluctuation device (produced by
Thought Technology). Two sensors were placed on the participant’s hand, one touching the
palm and the second attached to the pointer finger. Once sensors were attached, a very slight
electrical current ran through the electrodermal skin fluctuation device, which recognized
variances in salt and water from sweat glands. When the skin’s surface produces more sweat, the
electrical conductivity increases, reflecting a higher reading on the device and indicating higher
levels of stress. The electrodermal skin fluctuation measure was administered during each of the
12 individual therapy sessions.
Physiological arousal was measured weekly during sessions using skin conductance
fluctuations per minute and two measures were explored. An average measurement was
calculated across each session and change in average measurement was calculated. Secondly,
each session was divided into 10-minute epochs. An average measurement was calculated for
each 10-minute epoch and the peak rate epoch was determined. Change in peak rate epoch
across sessions was calculated.
Data Analysis
All data were entered into SPSS Version 21.0. Initial frequencies were examined for
outliers and checked against raw data. Exploratory analyses were performed on the data to
create descriptive statistics on the sample. Alpha coefficients were computed to examine each
scale’s reliability. The associations between emotion dysregulation and other independent
variables, such as treatment condition and symptom severity at baseline, were examined through
correlation analyses. Relationships among dependent variables and demographic and
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background variables were performed using correlations, chi squares, t tests, and ANOVAs to
check for possible covariates. Research questions were answered using 2 × 2 × 2 ANOVAs. See
Figure 1 for sample 2 × 2 × 2 ANOVA.

Figure 1. Will treatment type modify the relationship between baseline dysregulation, and
outcomes of interest?
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CHAPTER 4: RESULTS
Baseline Characteristics
Table 1 depicts demographic characteristics in addition to variables related to
pretreatment substance use, PTSD symptoms, and emotion dysregulation. To review,
participants ranged in age from 20 to 64, with a mean age of 39.8 years (SD = 11.9). The sample
was 66.3% male (n = 53) and 33.8% female (n = 27). Over 75% of the participants indicated
they were a racial/ethnic minority, with 56.3% identified as African American (n = 45) and
21.3% identified as Hispanic (n = 17). Over 90% of the sample was born in the United States (n
= 73) and 93.5% of participants (n = 72) indicated that English was their first language. In terms
of education, participants attended, on average, 13.07 years of schooling (SD = 3.0). At baseline
assessment, 67.5% were employed in some fashion. Regarding service utilization prior to study
enrollment, 23.6% of participants (n = 17) reported receiving previous outpatient treatment for
psychological problems; 55.6% (n = 40) reported receiving previous inpatient treatment for
psychological problems; and 23.9% of participants (n = 17) reported previous trauma specific
treatment. At baseline assessment, 54.1% of the sample (n = 40) indicated they had at some
point been prescribed psychotropic medication and nearly 20% of the sample (n = 13) reported at
least one suicide attempt.
Approximately 60% of participants met DSM-IV-TR criteria for PTSD (n = 50) while the
remaining 37.5% demonstrated symptoms consistent with subthreshold PTSD (n = 30). The
total sample had a mean DERS score of 90.9 (SD = 22.4). The subjects with DERS scores above
the mean were considered to be high dysregulators (48.8%; n = 39); participants with DERS
scores below the mean were considered to be low dysregulators (51.3%; n = 41).
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Table 1
Baseline Participant Characteristics
Total
(N = 80)
Variable
Age
Gender (% female)
Race/ethnicity (%)
African American/Black
Caucasian
Latino
Other
Marital status (%)
Married
Single
Divorced/separated
Years of education
Employment (%)
Employed
Unemployed
Student/retired/disabled
PTSD diagnosis (% full)
CAPS total, Baselinea
Substance use days in last 7
DERS total score, Baseline
Therapy sessions attended
Prior mental health treatment
Inpatient (% Yes)
Outpatient (% Yes)
Trauma specific treatment
(% Yes)
Treatment group (% RPT)

COPE
(n = 40)

RPT
(n = 40)

M or %

SD

M or %

SD

39.8
33.8

11.9

38.8
35.0

11.9

M or %

SD

40.8
32.5

12.0

56.3
18.0
21.3
3.8

52.5
20.0
22.5
5.0

60.0
17.5
20.0
2.5

17.7
25.3
57.0
13.1

3.0

15.0
65.0
20.0
13.2

3.1

20.5
48.7
30.8
12.9

3.0

17.4
2.5
22.4
4.6

71.8
10.3
17.9
65.0
52.9
4.5
89.5
5.8

16.3
2.5
23.0
4.6

63.2
18.4
18.4
60.0
54.5
4.3
92.2
7.5

18.6
2.4
21.9
4.5

67.5
14.3
18.2
62.5
53.7
4.4
90.9
6.7
55.6
23.6
23.9

56.8
22.9
22.9

54.3
24.3
25.0

50.0

0.0

100.0

Note. Values are either means (with standard deviations) or percentages. COPE = Concurrent Treatment of PTSD
and Substance Use Disorders Using Prolonged Exposure; RPT = relapse prevention therapy. PTSD = posttraumatic
stress disorder; CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation Scale.
There were no statistical differences between treatment groups on any pretreatment variable.
a
Variable included in randomization stratification.
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Half of the sample was randomized to the COPE treatment (n = 40) and half was
randomized to RPT (n = 40). Overall, treatment attendance ranged from 0 to 12 sessions;
participants attended a mean of 6.7 sessions (SD = 4.6). There were no statistically significant
differences between treatment groups for the various baseline characteristics.
Descriptive Statistics
Table 2 depicts descriptive statistics for variables to be analyzed during correlation and
regression analysis. CAPS, Substance use days in last 7, and DERS, variables were all within
acceptable limits for skewness and kurtosis. All measures had good to excellent reliability
(α > .8).
In Table 3, correlation analyses examined potential non-hypothesized relationships
between the dependent and independent variables. Pearson coefficients showed there was a
significant positive association between the CAPS follow-up and days used follow-up, r(41) =
.36, p = .02; DERS baseline and DERS follow-up, r(38) = .67, p < .01; CAPS baseline and
CAPS follow-up, r(41) = .57, p < .01; and CAPS baseline and DERS follow-up, r(38) = .40, p =
.01. These correlations, while not hypothesized, are in the expected direction.
Research Question 1: Analysis
Pearson correlation analyses were conducted to determine whether there were
relationships among baseline emotion dysregulation, as measured by the DERS, and baseline
PTSD and SUD, as measured by the CAPS score, and substance use days in the last 7 at baseline
among individuals with PTSD.

Table 2
Descriptive Statistics: Substance Use, Emotion Dysregulation, and PTSD Symptoms at Baseline
M

SD

Min

Max

Skewness

Kurtosis

Cronbach’s α

53.73

17.36

18.00

94.00

.37

−0.42

.81

4.40

2.45

0.00

7.00

−.39

−1.21

DERS baseline (n = 80)

90.90

22.36

50.00

160.00

.40

−.07

.93

CAPS follow-up (n = 41)

37.25

24.77

0.00

100.00

.53

−.37

.93

1.83

2.41

0.00

7.00

1.05

−.23

80.22

21.18

46.00

124.00

.25

−1.05

Variable
CAPS baseline (n = 80)
Substance use days in last 7
Baseline (n = 80)

Substance use days in last 7
Follow-up (n = 41)
DERS follow-up (n = 38)

.93

Note. CAPS = Clinician-Administered PTSD Scale. DERS = Difficulties in Emotion Regulation Scale.
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Table 3
Correlation Analysis of Independent and Dependent Variables
1
1. Days used baseline

2

3

4

5

—
.14

—

3. DERS baseline

−.12

−.03

4. DERS follow-up

−.29

.08

.674**

—

5. CAPS baseline

.14

.17

.41**

.40*

—

6. CAPS follow-up

.06

.36*

.07

.31

.54**

2. Days used follow-up

6

—

—

Note. CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation Scale.
*
p ≤ 0.05. **p ≤ 0.01.

40

41
As shown in Table 4, there was no significant correlation between the DERS baseline
total score and substance use days in the last 7 at baseline. A statically significant positive
association was found between the CAPS baseline total score and the DERS baseline total score,
r(80) = .41, p < 0.01, with DERS baseline total score explaining 17.4% of the variability in
CAPS baseline total score. Baseline emotion dysregulation is associated with baseline PTSD
symptoms but not with baseline substance use.
Research Question 2: Analysis
A 2 × 2 × 2 (DERS group by treatment type by time) repeated measures ANOVA was
conducted to determine whether treatment type moderates the relationship between baseline
dysregulation, as measured by the DERS, and treatment outcomes, as measured by the CAPS
and substance use days in the last 7 at follow-up.

Table 4
Correlation Analysis Among Baseline DERS, Substance Use Days in the Last 7 Days, and CAPS
Scores (N = 80)
Variable

1

1. DERS, Baseline

—

2. CAPS, Baseline

.41**

3. Substance use days in
the last 7, Baseline

−0.12

2

3

—
.14

—

Note. CAPS = Clinician-Administered PTSD Scale. DERS = Difficulties in Emotion Regulation Scale.
*
p ≤ 0.05. **p ≤ 0.01.
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Table 5 presents the results of the multivariate tests and shows a significant time effect,
F(1, 37) = 25.78, p < .01, partial η2 = .59, and a trend for the hypothesized 2 × 2 × 2 interaction,
F(1, 37) = 2.7, p = .08, partial η2 = .13. Since the sample size is fairly small and the effect size
of the interaction effect was medium (explaining 13% of the variability in outcome measures),
univariate tests were conducted. Tables 6 and 7 present results from the univariate tests.
As shown in Table 6, time was found to be significant for days used, F(1, 37) = 28.67, p
< .01, partial η2 = .44. Additionally, there was a DERS group by treatment group interaction on
PTSD outcomes, regardless of time, F(1, 37) = 5.06, p =.03, partial η2 = .12. As a result, t tests
were used to determine specifically which groups differed significantly.
As shown in Table 8, among high dysregulators, the RPT group had higher mean CAPS
total score (M = 57.04, SE = 5.37) as compared to the COPE group (M = 42.83, SE = 6.41)
whereas among low dysregulators, RPT group did not have a significantly different mean CAPS
total score as compared to the COPE group (Mdifference = 5.32, SE = 8.36, p =.53), regardless of
time. This difference indicates an unintentional lack of randomization on the PTSD severity
scores. See Figure 2 for a graphical depiction of the group differences.
As shown in Table 7, time was found to be significant for days used, F(1, 37) = 33.84,
p < .01, partial η2 = .48. Additionally, the Time × Treatment Group × DERS Group interaction
was found to be significant for days used, F(1, 37) = 5.281, p < .027, partial η2 = .125. As a
result, t tests were used to determine specifically which groups differed significantly.

Table 5
Multivariate Tests: Change in Outcomes Over Time by Baseline DERS Group by Treatment Group
(N = 38)

Value

Effect

Between subjects

Within subjects

Pillai’s Trace
Hypothesis
Error
df
df

F

p

partial
η2

Intercept

.90

160.78

2

36

.01**

.90

DERS group

.11

2.26

2

36

.12

.11

Treatment group

.06

1.18

2

36

.32

.06

DERS group × Treatment group

.12

2.46

2

36

.10

.12

Time

.59

25.78

2

36

.01**

.59

Time × DERS group

.08

1.52

2

36

.23

.08

Time × Treatment group

.04

.66

2

36

.52

.04

Time × DERS group × Treatment group

.13

2.70

2

36

.08

.13

Note. CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation.
*
p ≤ 0.05. **p ≤ 0.01.
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Table 6
Univariate Tests for PTSD Symptoms by Time by Treatment Group by DERS Group (N=38)
Effect

MS

df

SS

F

p

partial η2

.01**

.44

Within subject effects
Time

6344.48

1

6344.48

28.67

591.60

1

591.60

2.67

.11

.07

0.02

1

0.02

.00

.99

.00

Time × DERS group × Treatment group

187.97

1

187.97

.85

.36

.02

Error

221.30

37

8188.04

936.19

1

936.19

1.63

.21

.04

72.01

1

72.01

0.13

.73

.003

2911.62

1

2911.62

5.06

.03*

.12

575.79

37

21304.10

Time × DERS group
Time × Treatment group

Between subjects effects
DERS group
Treatment group
DERS group × Treatment group

Error

Note. CAPS = Clinician-Administered PTSD Scale. DERS = Difficulties in Emotion Regulation.
*
p ≤ 0.05; **p ≤ 0.01
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Table 7
Univariate Analysis for Substance Use Symptoms by Time by Treatment Group by DERS Group
(N=38)
Effect

MS

df

SS

F

partial η2

p

Within subject effects
Time

0.01**

161.60

1

161.60

33.84

Time × DERS group

0.62

1

0.62

0.13

.72

Time × Treatment group

6.31

1

6.31

1.32

.26

Time × DERS group × Treatment group

25.22

1

25.22

221.30

37

8188.04

DERS group

11.07

1

Treatment group

12.14

DERS group × Treatment group

Error

Error

0.48
0.003
0.03

*

5.28

.03

0.13

11.07

1.66

.21

0.04

1

12.14

1.82

.19

0.05

3.43

1

3.43

0.51

.48

0.01

6.69

37

247.34

Between subjects effects

Note. CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation.
*
p ≤ 0.05. **p ≤ 0.01.

Table 8
t Tests for Baseline DERS Group by Treatment Group on CAPS Score, Regardless of Time
DERS Group
Low
dysregulation
High
dysregulation

Treatment
Group

Mean (SD)

RPT (n = 14)

37.80 (4.54)

COPE (n = 10)
RPT (n = 10)

48.15 (5.37)
57.04 (5.37)

COPE (n = 7)

42.83 (6.41)

Mean
Difference

SE

p

5.32

8.36

.53

19.24

7.03

.009**

Note. CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation.
*
p ≤ 0.05. **p ≤ 0.01.
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Figure 2. Baseline DERS group by treatment group on CAPS score (N = 41). CAPS =
Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation; COPE =
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure; RPT =
relapse prevention therapy.

As shown in Table 9, the high baseline DERS group that received RPT treatment showed
no change in days used. All other groups, that is the high baseline DERS group that received
COPE treatment, the low baseline DERS group that received COPE treatment, and the low
baseline DERS group that received RPT treatment, showed significant change in days used from
baseline to follow-up (see Table 9 for means pre- and post-treatment). See Figure 3 for a
graphical depiction of the interaction.
Research Question 3: Analysis
A 2 × 2 × 2 (DERS group by treatment type by time) repeated measures ANOVA was
conducted to determine whether treatment type moderates the relationship between baseline
dysregulation, as measured by the DERS, and change in emotion dysregulation, as measured by
change in DERS total score.
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Table 9
t Tests for Time by Treatment Group by DERS Group on Substance Use
Treatment
Group

Baseline M (SD)

Follow-up M (SD)

t

Low dysregulation

RPT (n = 14)
COPE (n = 10)

4.86 (2.21)
5.50 (2.46)

1.21 (2.33)
3.00 (2.75)

4.885
2.277

13
9

.001**
.049*

High
dysregulation

RPT (n = 10)
COPE (n = 7)

3.20 (2.94)
5.29 (1.98)

2.20 (2.44)
0.86 (1.46)

0.866
5.894

9
6

.409
.001**

DERS Group

df

p

Note. CAPS = Clinician-Administered PTSD Scale; DERS = Difficulties in Emotion Regulation; COPE =
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure; RPT = relapse prevention
therapy.
*
p ≤ 0.05. **p ≤ 0.01.

Figure 3. t Tests for time by treatment group by DERS group on substance use (n = 41). COPE
= Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure;
RPT = relapse prevention therapy.
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Table 10 presents the results of the univariate tests and shows a significant effect of time,
F(1, 34) = 7.11, p = .01, partial η2 = .17, and a significant Time × DERS effect, F(1, 34) = 6.25,
p = .02, partial η2 = .16, and a trend for the hypothesized 2 × 2 × 2 interaction, F(1, 34) = 3.40,
p = .07, partial η2 = .09). Since the sample size is fairly small and the effect size of the three-way
interaction effect is small to medium (explaining 9% of the variability in outcome measures),
post-hoc t tests were conducted. Univariate tests also revealed a DERS group effect on change
in DERS, regardless of time, F(1, 34) = 45.96, p <.001, partial η2 = .58. As a result, t tests were
used to determine specifically which groups differed significantly. Tables 11 through 13 present
results from the post-hoc t tests.

Table 10
Univariate Tests for Change in DERS by Time by Treatment Group by DERS Group (N = 38)
Effect

MS

df

SS

F

p

partial
η2

Within subject effects
908.05

1

908.05

7.11

.01**

.17

24.62

1

24.62

0.19

.66

.01

Time × DERS group

798.61

1

798.61

6.25

.02*

.16

Time × DERS group × Treatment group

434.06

1

434.06

3.40

.07

.09

Error

127.72

34

4342.32

529.24

1

529.24

1.70

.202

Time
Time × Treatment group

Between subjects effects
Treatment group
DERS group
DERS group × Treatment group

Error

14355.25

1

14355.25

45.96

.001

704.02

1

704.02

2.25

.142

106118.74

34

106118.74

Note. DERS = Difficulties in Emotion Regulation.
*
p ≤ 0.05. **p ≤ 0.01.

.05
**

.58
.06
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Table 11
t Tests for Time by DERS Group on Change in DERS

DERS Group

n

Baseline
M (SD)

Follow-Up
M (SD)

t

df

p

Low dysregulation

23

71.72 (10.44)

70.78 (16.06)

.29

22

.77

High dysregulation

15

107.40 (13.66)

94.71 (20.22)

2.82

14

.01*

Note. DERS = Difficulties in Emotion Regulation; COPE = Concurrent Treatment of PTSD and Substance Use
Disorders Using Prolonged Exposure; RPT = relapse prevention therapy.
*
p ≤ 0.05. **p ≤ 0.01.

Table 12
t Tests for Time by Treatment Group by DERS Group on Change in DERS
DERS Group

Treatment Group

Baseline M (SD)

Follow-Up M (SD)

t

df

p

Low dysregulation

RPT (n = 13)
COPE (n = 10)

73.00 (12.1)
70.07 (8.12)

68.77 (18.4)
73.39 (12.85)

0.92
−0.78

12
9

.377
.458

High dysregulation

RPT (n = 9)
COPE (n = 6)

109.66 (10.68)
104.00 (17.8)

101.89 (16.98)
83.92 (21.25)

1.66
2.38

8
5

.135
.063

Note. DERS = Difficulties in Emotion Regulation; COPE = Concurrent Treatment of PTSD and Substance Use
Disorders Using Prolonged Exposure; RPT = relapse prevention therapy.
*
p ≤ 0.05; **p ≤ 0.01

Table 13
t Tests for Baseline DERS group on Change in DERS, Regardless of Time
DERS Group (n)

Mean (SD)

Low DERS group (24)

71.31 (2.63)

High DERS group (17)

99.87 (3.30)

Mean
Difference

SE

28.56

4.21

Note. DERS = Difficulties in Emotion Regulation Scale.
*
p ≤ 0.05. **p ≤ 0.01.

p

0.01**
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As shown in Table 11, the high baseline DERS group showed a significant change in
DERS at follow-up (Mpre = 107.40, SD = 13.66; Mpost = 94.71, SD = 20.22, p = .01) as compared
to the change in DERS found in the low baseline DERS group at follow-up.
As shown in Table 12, the high baseline DERS group that received COPE treatment
showed a change in DERS at follow-up at a trend level (Mpre = 104.00, SD = 17.80; Mpost =
83.93, SD = 21.25, p = .063). All other groups, that is the high baseline DERS group that
received RPT, the low baseline DERS group that received COPE treatment, and the low baseline
DERS group that received RPT, showed no significant change DERS total from baseline to
follow-up (see Table 12 for means pre- and post-treatment). See Figure 4 for a graphical
depiction of the interaction.

Figure 4. t Tests for time by treatment group by DERS group on change in DERS (n = 38).
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Lastly, as shown in Table 13, the high DERS group had higher mean DERS total score
(M = 99.87, SE = 3.30) as compared to the low DERS group (M = 71.31, SE = 2.63), regardless
of time. This difference is a result of the high–low DERS grouping created for the 2 × 2 × 2
analysis.
Case Illustration
The high baseline DERS group that received COPE treatment showed a trend level
change in DERS at follow-up (Mpre = 104.00, SD = 17.80; Mpost = 83.93, SD = 21.25, p = .063).
All other groups, specifically the high baseline DERS group that received RPT treatment, the
low baseline DERS group that received COPE treatment, and the low baseline DERS group that
received RPT treatment, showed no significant change DERS total from baseline to follow-up.
To further explore the change in DERS over time among highly dysregulated individuals
undergoing COPE, one case was selected for a case illustration. The participant’s physiological
arousal during sessions was examined using a skin conductance measure and both skin
conductance level, a measure of overall arousal level, and skin conductance rate, a measure of
the number of fluctuations in arousal per minute, were calculated.
Table 14 depicts demographic characteristics in addition to variables related to
pretreatment and follow-up substance use, PTSD symptoms, emotion dysregulation, and
physiological arousal. To review, the participant was a 51-year-old African American/Black
male with some college education. He received 12 sessions of treatment and showed a 38-point
reduction in emotion dysregulation, as measured by the DERS; a 28-point decrease in CAPS
score; and a 6-day decrease in substance use days in the last 7 at follow-up.
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Table 14
Case Illustration Participant Characteristics
Variable
Age
Gender (% male)
Race/ethnicity (%)
African American/Black
Caucasian
Latino
Other
Years of education
Therapy sessions attended
Baseline DERS group (% high dysregulation)
DERS total score, Baseline
DERS total score, Follow-up
CAPS total, Baseline
CAPS total, Follow-up
Substance use days in last 7, Baseline
Substance use days in last 7, Follow-up
SCR, Session 1 (peaks per minute)
SCR, Session 12 (peaks per minute)
% Change in SCR
SCL, Session 1
SCL, Session 12
% Change in SCL

COPE
(n = 1)
51
100
100
0
0
0
14
12
100
98
60
28
0
7
1
1.61
1.06
−34
2.41
1.34
−44

Note. Values are either raw scores or percentages. COPE = Concurrent Treatment of PTSD and Substance Use
Disorders Using Prolonged Exposure. PTSD = posttraumatic stress disorder; CAPS = Clinician-Administered
PTSD Scale; DERS = Difficulties in Emotion Regulation Scale; SCR = skin conductance rate; SCL = skin
conductance level.

Figure 5 depicts the physiological arousal over the course of treatment. With regards to
physiological arousal, as measured by SCR, the COPE participant showed a steady increase in
physiological arousal, peaking in the fourth session before his arousal decreased over the course
of the last eight sessions.
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Figure 5. Change in physiological arousal through the course of treatment.

Figure 6 depicts the COPE participant’s skin conductance during the first and last (12th)
COPE session. The COPE participant had an average SCR of 1.61 peaks per minute and an
average SCL of 2.41 micro Siemens during Session 1. During the 12th session, the COPE
participant had an average SCR of 1.06 peaks per minute and an average SCL of 1.34 micro
Siemens. As compared to Session 1, the COPE participant’s overall arousal was 44% lower with
34% fewer fluctuations during Session 12, indicating a lower level of arousal during the final
session of treatment as compared to the initial session.
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Figure 6. Skin conductance during first and last COPE session.
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CHAPTER 5: DISCUSSION
Emotion dysregulation has been observed to be a shared feature of both PTSD and SUD
(Hien et al., 2005). Treatments for these complex comorbid problems utilize a variety of
approaches. However, to date, few studies have examined the effect of the various available
treatments on emotion dysregulation in this population. The present study attempted to extend
the research on emotion dysregulation among the comorbid PTSD and SUD population. It
examined features associated with emotion dysregulation, associating dysregulation with other
psychiatric symptoms affecting this clinical population. Specifically, the study focused on
baseline emotion dysregulation as a predictor of treatment outcomes and used a longitudinal
design to assess changes in emotion dysregulation over time to determine the mutability of this
complex factor in response to treatment. Given the seriousness and prevalence of PTSD and
SUD (van Dam et al., 2010), and the many impediments they pose to treatment efficacy, a more
refined understanding of emotion dysregulation could support improved conceptualization and
implementation of psychotherapeutic interventions for this population.
A detailed discussion of study findings is presented in the next five sections, beginning
with an overview of the main findings, briefly summarizing the results related to each of the
research questions. Additionally, research and clinical implications will be reviewed. Lastly,
limitations and future directions for research will be presented.
Summary of Main Findings
Emotion dysregulation is inherent to many forms of psychopathology (Bradley et al.,
2011). Previous studies using non-clinical and community samples found associations between
PTSD symptom severity and overall emotion dysregulation (Weiss et al., 2013). Similar
associations were observed among a treatment-seeking cocaine dependent sample (McDermott et

56
al., 2009). People with severe PTSD and SUD symptoms are assumed to have high
dysregulation. This study examined features associated with baseline emotion dysregulation
among a comorbid PTSD and SUD population and indeed, found a positive association between
the CAPS baseline total score and the DERS baseline total score. However, no significant
correlation between the DERS baseline total score and substance use days in the last 7 at baseline
was found. Baseline emotion dysregulation was associated with baseline PTSD symptoms, but
not with baseline substance use among people with comorbid PTSD and SUD. The present
study reinforces the findings of Weiss et al. (2013); Bonn-Miller, Vujanovic, Boden, and Gross
(2011); and Tull, Barrett, McMillan, and Roemer (2007). Greater difficulty in regulating
emotions is associated with PTSD symptom severity. Future research studies involving similar
populations should take these findings into consideration.
Self-medicating with alcohol and drugs can provide temporary relief from the
dysregulated feeling states that are characteristic of PTSD (Hien et al., 2009). Because of their
long-standing chronic use of substances to manage affect, individuals with PTSD and SUD may
not be aware of experiencing problems with emotion regulation. Unlike the CAPS which is a
30-item clinically administered interview protocol that is able to capture the nuances of multiple
PTSD symptoms, the substance use measure utilized in this study focused on substance use
frequency alone. It is noteworthy that frequency is only one symptom of a SUD and may likely
not have been a sensitive enough measure to capture how emotion regulation and substance use
are related. Additionally, though this study considered several aspects of emotion dysregulation
including, impulse control, emotional awareness, access to regulation strategies, and emotional
clarity, it is possible that the construct did not tap into addiction-related symptoms. It is also
possible that certain episodic substance use patterns are not correlated with the DERS, as the
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measure asks for an overall rating of one’s ability to manage strong emotions. Episodic use may
be indicative of varying levels of emotion dysregulation. In sum, it is possible that use needs to
be at a certain level and/or with a certain frequency to be correlated with dysregulation.
Exposure-focused treatments and skills-based treatments are premised on different
emphases with respect to emotion dysregulation. RPT aims to change behavior through a topdown approach, examining cognitions in relation to affect. COPE, the only exposure treatment
developed to treat SUD, utilizes a bottom-up fear habituation processing model. Specifically, the
second research question in the present study explored whether treatment type moderated the
relationship between baseline dysregulation, as measured by the DERS, and treatment outcomes,
as measured by the CAPS and substance use days in the last 7 at follow-up. Findings revealed a
significant three-way interaction: Time × Treatment Group × DERS Group was significantly
different across the substance use outcome measure. Specifically, the high baseline DERS group
that received COPE treatment, the low baseline DERS group that received COPE treatment, and
the low baseline DERS group that received RPT treatment all showed significant change in
number of days of use from baseline to follow-up; by contrast, the high baseline DERS group
that received RPT treatment showed no change in number of days of use.
These findings suggest that among highly dysregulated individuals with SUD and PTSD,
a treatment focusing solely on the SUD will not garner positive changes in substance use
frequency. These results provide a strong indicator that treatments that do not directly discuss or
integrate trauma cannot shift problematic substance use, especially among the highly
dysregulated participants. Not only is a treatment like COPE indicated, but indeed these findings
provide some suggestion that RPT may be contraindicated or even iatrogenic for highly
dysregulated people with comorbid PTSD and SUD. These findings support Brady et al. (2001),
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Najavits et al. (2005), and most recently, Mills et al. (2012), in challenging the commonly held
view that patients with comorbid PTSD and SUD are inappropriate candidates for prolonged
exposure (Becker, Zayfert, & Anderson, 2004). Though it has been theorized that individuals
with comorbid PTSD and SUD are too high risk to engage in exposure-based treatments,
empirical research including the present study, have shown evidence to the contrary. Patients
with comorbid PTSD and SUD have shown the ability to tolerate and benefit from traumafocused treatment.
Additionally, treatment group by DERS group, regardless of time, was found to be
significant for PTSD symptoms indicating a difference in the level of PTSD symptoms between
the two treatment groups. More specifically, among high dysregulators, the RPT group had
higher mean CAPS total score as compared to the COPE group, whereas among low
dysregulators, RPT group did not have a significantly different mean CAPS total score as
compared to the COPE group, regardless of time. This difference indicates an unintentional lack
of randomization at baseline. Specifically, since participants were not matched on baseline
emotion dysregulation during the randomization phase of the study, the RPT group had higher
CAPS total score, regardless of time. The groups were not equivalent on this variable.
Randomization presumes equivalence across groups. If equivalence is not established,
group comparisons are problematic. It is difficult, however, to always know which variables are
important and should be considered in the randomization process. Since the present study
evidenced that emotion dysregulation is related to PTSD symptom severity, future studies
focusing on individuals with PTSD should consider baseline dysregulation as a factor for
randomization. One challenge to considering baseline dysregulation in the randomization
process is the difficulty in defining high verses low dysregulation in the study sample during the
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randomization phase. The present study calculated a sample mean DERS score and grouped
those above the mean into the high dysregulation group and those below the mean into the low
dysregulation group. Randomizing on dysregulation would require the a priori classification of
dysregulation severity, which is not yet established in the literature.
Emotion regulation describes the processes by which individuals influence expression of
emotions, when emotions arise, and how they are experienced (Hien et al., 2009). To the extent
that certain emotion regulatory strategies are theorized to be more adaptive than others, it can be
hypothesized that psychologically based treatments may affect emotion regulatory capacities.
For example, individuals with comorbid PTSD and SUD often have a limited range of accessible
emotional coping skills and are frequently over reliant on avoidant strategies in an attempt to
manage intense feelings. Exposure therapy, directly and experientially, addresses emotion
regulation problems and associated physiological arousal through habituation to disrupted fear
responses in the service of assimilating and integrating overwhelming experiences. RPT for
comorbid PTSD and SUD, on the other hand, focuses on identifying emotional states for the
purpose of coping and managing intense emotion, so the treatment mainly works on developing
skills and building coping strategies.
Specifically, the third research question in the present study examined whether treatment
type moderated the relationship between baseline dysregulation and dysregulation at follow-up.
Findings revealed (at a trend level) that those in the high baseline DERS group who received
COPE treatment had lower DERS at follow-up. In contrast, all other groups, specifically the
high baseline DERS group that received RPT, the low baseline DERS group that received COPE
treatment, and the low baseline DERS group that received RPT, showed no significant change
DERS total from baseline to follow-up.
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These results provide a speculation that among people with PTSD and SUD, those with
high levels of emotion dysregulation may be particularly able to make use of the COPE
treatment model. Engagement in a treatment that directly addresses trauma memories may
positively impact emotion regulation capacities among those with particular difficulty in that
domain. By reducing anxiety and increasing awareness, individuals no longer need to engage in
emotional and behavioral avoidance. By confronting the trauma directly, it is possible to find
some degree of emotional mastery over overwhelming traumatic experiences.
Additionally, the supplemental analysis of the skin conductance data provided descriptive
information that depicted the physiological arousal of one participant in the high baseline DERS
group who received COPE treatment. The participant was a 51-year-old African
American/Black male with some college education. He received 12 sessions of treatment and
showed a 38-point reduction in emotion dysregulation as measured by the DERS; a 28-point
decrease in CAPS score; and a 6-day decrease in substance use days in the last 7 at follow-up.
His physiological arousal pattern showed a decrease in arousal over time and was consistent with
the change (at a trend level of p = .063) found in the high dysregulation COPE group’s change in
DERS at follow-up.
Clinical Implications
Experts in the field of substance abuse treatment have historically been hesitant to use
prolonged exposure to treat individuals with comorbid PTSD and SUD. Exposure-based
behavioral therapies are suspected to be contraindicated for people with addictions for fear of
relapse, treatment dropout, increased acting-out behaviors, and dysregulation (van Minnen et al.,
2012). In sum, prolonged exposure has been considered inappropriate for use among patients
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with SUD as it was believed that these patients may be unable to cope with the intense emotions
triggered during exposure to trauma memories (Foa & Rothbaum, 1998).
According to the results of this dissertation study, highly dysregulated persons with
PTSD and SUD undergoing COPE exhibited positive changes in emotion dysregulation, while
the other groups did not. Additionally, highly dysregulated individuals at baseline benefitted
more from COPE than RPT with respect to change in substance use. While RPT is an
intellectual skill-based approach focusing on cognitions and behavior, COPE uses both cognitive
strategies and emotion-focused exercises to more experientially and directly address affective
experiences. These results provide additional support for the use of integrated treatments for
comorbid SUD and PTSD (Back, Waldrop, Hien, & Brady, 2006; Hien, Campbell et al., 2010)
among highly dysregulated individuals.
The sequential model of care for comorbid PTSD and SUD treats the substance use first
and defers treatment of trauma-related issues. The clinical rationale behind deferring trauma
treatment relates to a fear of that unaddressed substance abuse could impede other therapeutic
efforts and potentially cause relapse (Pitman et al., 1991; as cited in Back et al., 2006). While
RPT is often considered the gold standard addiction treatment (Carroll et al., 1994; as cited in
Hien et al., 2004) the results from this exploratory study indicate that high baseline dysregulation
renders RPT ineffective in a comorbid PTSD and SUD population. This exploratory study
highlights the importance of directly and explicitly addressing trauma to improve substance use
outcomes for highly dysregulated individuals with this comorbidity.
Patients sharing DSM-IV-TR diagnoses of PTSD and SUD are not a homogenous
population. This analysis demonstrated that a one-size-fits-all approach has limited value for
such comorbid conditions and underscored the importance of assigning patients to treatments
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based on their specific needs and characteristics. Specifically, different degrees of emotion
dysregulation should be accounted for in order to provide a patient with matched clinical care.
This dissertation indicates that an assessment of pretreatment emotion dysregulation can assist
treatment efficacy. Additionally, this exploratory study furthers the work of Mills et al. (2012)
by emphasizing that highly dysregulated populations with PTSD and SUD are able to both
tolerate and benefit from exposure treatment.
Traditional intervention research has focused on comparing how groups of individuals
receiving an experimental treatment compared to a control group. This approach provides
information about treatments for selected groups of people, but says little about choosing the best
treatment for a specific individual. As the health care landscape shifts to providing more
personalized care, it is important to consider individual characteristics, like emotion
dysregulation, to optimize outcomes. Researchers are developing ways to better predict patients’
responses to targeted treatments; however, determining which factors have the most clinical
significance is paramount (Hamburg & Collins, 2010). The success of personalized medicine
depends on having accurate assessments that identify patients who can benefit from targeted
therapies (Hamburg & Collins, 2010). This study may help to guide treatment customization
based on interactions between emotion dysregulation and intervention focus. Trauma processing
psychotherapies, like COPE, that provide opportunity for meaning-making and trauma
integration, may be better aligned for individuals who struggle in those domains as they pertain
to impairments in emotion dysregulation.
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Research Implications
Findings from an ANOVA identified a relationship between pretreatment levels of
dysregulation and CAPS scores by treatment type. Among high dysregulators, the RPT group
had higher mean CAPS total score as compared to the COPE group, whereas among low
dysregulators, the RPT group did not have a significantly different mean CAPS total score as
compared to the COPE group, regardless of time. This difference is indicative of an
unintentional lack of randomization at baseline. This finding suggests that it is appropriate to
stratify study samples by emotion dysregulation, as it is frequently associated with outcomes of
interest in a comorbid PTSD and SUD population. Future studies involving samples with PTSD
should consider randomizing on this factor.
Limitations and Future Directions
This exploratory study suggests the importance of directly discussing trauma in treatment
for highly dysregulated people with comorbid PTSD and SUD. These results, however, must be
interpreted with caution due to the small sample size. The interaction effects demonstrated
within this dissertation indicate the importance of continuing the essential line of inquiry into
emotion dysregulation and treatment matching with studies using larger samples.
Emotion dysregulation is known to be correlated with substance use severity (Suh et al.,
2008); however, this study demonstrated that baseline emotion dysregulation was not associated
with baseline substance use frequency among people with comorbid PTSD and SUD. Future
research on this topic should look deeper into the data to address a more complete picture of the
relationship between baseline substance use and baseline emotion dysregulation. Future studies
should include measures of not only substance use frequency, but of quantity, cravings, and
periods of abstinence. The Addiction Severity Index composite score, for example, could be
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used to better capture the complexities of substance use severity, as it accounts for the impact of
substance use on living. Additionally, this study collapsed all categories of substances together
(i.e., alcohol, cannabis, cocaine, etc.) when describing substance use. Alternatively, separating
out classes of drugs may provide a more accurate picture of use patterns.
Emotion dysregulation has multiple facets. This study used a total composite score from
the DERS self-report measure. Future research might benefit from looking at specific
dimensions of emotion dysregulation. For example, the DERS can be broken down into four
indices: (1) awareness and understanding of emotions; (2) acceptance of emotions; (3) the ability
to engage in goal-directed behavior, and refrain from impulsive behavior when experiencing
negative emotions; and (4) access to emotion regulation strategies perceived as effective. These
indices may all function differently with respect to PTSD and SUD. Additionally, future studies
may benefit from using a less dichotomous measure of emotion dysregulation. By
acknowledging that emotion dysregulation exists on a spectrum, future studies might be
advantaged by considering certain levels of emotional expressiveness or dysregulation to be
advantageous, normative, or even healthy.
This study relied heavily on the use of an emotion dysregulation self-report measure.
The case illustration, however, utilized skin conductance data. The use of physiological
measures on a larger scale would address both the less subjective and less conscious aspects of
arousal and potentially dysregulation. While skin conductance is widely used to index
sympathetic arousal, it generally does not differentiate between positive and negative emotion
(Dawson, Schell, & Filion, 2007). Additionally, approximately 10 to 25% of participants are
estimated to be hypo-responsive with respect to their electrodermal response; it may not be
possible to obtain high quality skin conductance data measurements from some individuals
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(Braithwaite, Watson, Jones, & Rowe, 2013). Lastly, external factors such as temperature and
internal factors such as medication can affect galvanic skin response measurements, which can
lead to inconsistent results. Future studies may include heart rate variability as an additional or
alternative physiological measure of arousal. Research has shown that heart rate variability
reflects sympathetic as well as parasympathetic activation, and it is sensitive to changes in
arousal (Thayer, Ahs, Fredrickson, Stollers, & Wager, 2012).
Lastly, functional neuroimaging studies have implicated multiple regions of the brain,
including the right ventrolateral prefrontal cortex, amygdala, and dorsal anterior cingulate cortex,
in the regulation of positive and negative emotions (Etkin, Egner, & Kalisch, 2011; Ochsner &
Gross, 2005; Kalisch, 2009; Kanske, Heissler, Schönfelder, & Wessa, 2011). It has been
observed that dysfunction in these regions can lead to disturbances in emotional regulation (i.e.,
hypo- or hyper-arousal) and contribute significantly to impaired functioning underlying a variety
of psychological disorders, including PTSD and SUD (Teicher, 2000; Cooper et al., 1995;
Thorberg, & Lyvers, 2006). Further, fMRI studies directly examining the neural correlates of
emotion regulation among clinical populations could help to clarify the basic mechanisms by
which emotions are regulated and demonstrate the efficacy of specific treatments to ameliorate
deficits in this domain.
Conclusion
As a contribution to research and clinical practice, the current exploratory project
provided new evidence that exposure therapy can be tolerated by and beneficial to highly
dysregulated persons with PTSD and SUD. Contrary to expectations in the field, participants
randomized to receive the exposure-based intervention did not demonstrate poorer substance use
outcomes relative to those randomized to receive RPT. In fact, the present study findings
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provide strong support for the COPE treatment as more efficacious than RPT in reducing
emotion dysregulation and substance use frequency among individuals with high levels of
baseline dysregulation. Furthermore, this dissertation suggests that psychotherapy focusing only
on substance use (e.g., RPT) may be contraindicated for highly dysregulated individuals with
comorbid PTSD and SUD, as their substance use frequency did not decrease over time. This
study supports the idea that the complex presentations of individuals with PTSD and SUD should
not be a deterrent to providing trauma-focused treatment.
Knowing that specific alignments of emotion dysregulation and treatment types have
differential effects on therapeutic outcomes helps to better match individuals with treatments and
provide ways for therapy to be more effective. This exploratory study adds to what is known
about patient characteristics as pretreatment predictors of outcome and enhances the potential of
pairing patients with the types of treatment most likely to be helpful.
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